FOR LABORATORY RESEARCH ONLY Direct quotations · Minimum 1 box

Endocrine research

Long-acting CJC-1295 in GHRH-knockout mice: the model defines the claim

The experiment investigated a specific hormone-deficient mouse model, not normal human growth.

Preclinical studyPaper year: 2006CJC-1295 with DAC

01 / DESIGN

What was studied?

Mice lacking the GHRH gene were followed after exposure to an albumin-binding, long-acting CJC-1295 analogue. Investigators measured growth, body composition, bone lengths and pituitary-related measurements across experimental intervals.

02 / FINDINGS

What did the researchers report?

The reported growth and body-composition responses varied with exposure interval, with more complete normalization in one investigated condition. Pituitary RNA and tissue findings were consistent with changes in growth-hormone-producing cells.

03 / LIMITS

How should it be interpreted?

A gene-knockout model tests a defined deficiency and does not demonstrate growth or performance enhancement in healthy humans. The albumin-binding analogue is not interchangeable with no-DAC products. Animal timing experiments should not be converted into personal-use schedules or evidence of catalog-material safety.

Voltera Peptide editorial reading note. Based on the linked source record. Methods and corrections.

WhatsApp ↗